V
39.63
-0.08 (-0.19%)
| Previous Close | 39.70 |
| Open | 40.06 |
| Volume | 468,501 |
| Avg. Volume (3M) | 942,210 |
| Market Cap | 3,161,783,552 |
| Price / Earnings (TTM) | 36.69 |
| Price / Earnings (Forward) | 29.07 |
| Price / Sales | 7.46 |
| Price / Book | 2.97 |
| 52 Weeks Range | |
| Earnings Date | 5 Aug 2026 |
| Profit Margin | 7.13% |
| Operating Margin (TTM) | 7.03% |
| Diluted EPS (TTM) | 0.420 |
| Quarterly Revenue Growth (YOY) | 18.20% |
| Total Debt/Equity (MRQ) | 4.23% |
| Current Ratio (MRQ) | 5.10 |
| Operating Cash Flow (TTM) | 89.42 M |
| Levered Free Cash Flow (TTM) | 76.93 M |
| Return on Assets (TTM) | 1.94% |
| Return on Equity (TTM) | 2.86% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Diagnostics & Research (US) | Mixed | Bullish |
| Diagnostics & Research (Global) | Mixed | Bullish | |
| Stock | Veracyte, Inc. | Bullish | Bullish |
AIStockmoo Score
0.4
| Analyst Consensus | 2.0 |
| Insider Activity | -2.5 |
| Price Volatility | 1.0 |
| Technical Moving Averages | -2.5 |
| Technical Oscillators | 4.0 |
| Average | 0.40 |
|
Veracyte Inc is a genomic diagnostics company. It provides genomic diagnostic products and services to improve patient care against diseases such as thyroid cancer, lung cancer, and idiopathic pulmonary fibrosis. The firm's product portfolio consists of products such as Afirma analysis, Percepta, Envisia, and others. |
|
| Sector | Healthcare |
| Industry | Diagnostics & Research |
| Investment Style | Small Growth |
| % Held by Insiders | 0.54% |
| % Held by Institutions | 107.98% |
No data within this time range.
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| CHAMBERS REBECCA | - | 48.87 | -7,254 | -354,362 |
| FEBBO PHILLIP G. | - | 47.80 | -3,730 | -178,294 |
| LEITE JOHN | - | 48.87 | -18,034 | -891,932 |
| MCGUIRE ANNIE | - | 48.87 | -6,468 | -315,967 |
| STAPLEY MARC | - | 48.87 | -147,063 | -7,325,041 |
| WYGANT JONATHAN | - | 47.80 | -1,361 | -65,056 |
| Aggregate Net Quantity | -183,910 | |||
| Aggregate Net Value ($) | -9,130,651 | |||
| Aggregate Avg. Buy ($) | - | |||
| Aggregate Avg. Sell ($) | 48.66 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| LEITE JOHN | Officer | 04 Jun 2026 | Automatic sell (-) | 13,975 | 49.94 | 697,912 |
| STAPLEY MARC | Officer | 04 Jun 2026 | Automatic sell (-) | 138,051 | 49.94 | 6,894,267 |
| STAPLEY MARC | Officer | 04 Jun 2026 | Option execute | 138,051 | - | - |
| CHAMBERS REBECCA | Officer | 04 Jun 2026 | Automatic sell (-) | 3,561 | 49.94 | 177,836 |
| MCGUIRE ANNIE | Officer | 04 Jun 2026 | Automatic sell (-) | 3,176 | 49.94 | 158,609 |
| LEITE JOHN | Officer | 02 Jun 2026 | Disposed (-) | 4,059 | 47.80 | 194,020 |
| STAPLEY MARC | Officer | 02 Jun 2026 | Disposed (-) | 9,012 | 47.80 | 430,774 |
| FEBBO PHILLIP G. | Officer | 02 Jun 2026 | Disposed (-) | 3,730 | 47.80 | 178,294 |
| CHAMBERS REBECCA | Officer | 02 Jun 2026 | Disposed (-) | 3,693 | 47.80 | 176,525 |
| WYGANT JONATHAN | Officer | 02 Jun 2026 | Disposed (-) | 1,361 | 47.80 | 65,056 |
| MCGUIRE ANNIE | Officer | 02 Jun 2026 | Disposed (-) | 3,292 | 47.80 | 157,358 |
| Show more | ||||||
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |